A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
Launched by MASSACHUSETTS GENERAL HOSPITAL · Aug 2, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called SHIFT, is looking at a new digital app designed to help people who have undergone hematopoietic stem cell transplants (HCT) improve their sexual health and overall quality of life. The study aims to support survivors dealing with sexual dysfunction and emotional distress after their treatment. The trial is not yet recruiting participants, but it will include adults aged 18 and older who had a stem cell transplant at least three months ago and are experiencing sexual health issues that are causing them distress.
To join the study, participants will need to answer some screening questions to confirm their eligibility. It's important to note that the app will only be available in English and Spanish, so participants should be comfortable with either of these languages. Additionally, individuals with certain major mental health conditions that might affect their ability to participate will not be eligible. If you qualify and decide to take part, you can expect to use the app on your own, which is designed to help improve your sexual health and well-being after your transplant.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (\> 18 years) who underwent autologous or allogeneic HCT \> three months prior to study enrollment
- • Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions
- Exclusion Criteria:
- • Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial.
- • Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures.
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Boston, Massachusetts, United States
Coral Gables, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported